Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

The Topoisomerase I Poison CPT-11 Enhances the Effect of the Aurora B Kinase Inhibitor AZD1152 both In vitro and In vivo

(2009) J. S. Nair et al.   CLINICAL CANCER RESEARCH

Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells

(2009) T.-L. Cha et al.   CLINICAL CANCER RESEARCH

Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study

(2009) Joan H. Schiller et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents

(2009) John R. Pollard et al.   JOURNAL OF MEDICINAL CHEMISTRY

Clinical Experience with Aurora Kinase Inhibitors: A Review

(2009) D. S. Boss et al.   ONCOLOGIST

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate

(2008) Y. Dai et al.   BLOOD

Molecular Basis of Drug Resistance in Aurora Kinases

(2008) Fiona Girdler et al.   CHEMISTRY & BIOLOGY

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH

Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth

(2008) Y. G. Lin et al.   CLINICAL CANCER RESEARCH

Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells

(2008) W. Fiskus et al.   CLINICAL CANCER RESEARCH

Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines

(2008) Y. Arlot-Bonnemains et al.   ENDOCRINE-RELATED CANCER